|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
55,330,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Foghorn Therapeutics is a clinical-stage biopharmaceutical company discovering and developing medicines targeting genetically determined dependencies within the chromatin regulatory system. Co.'s product candidates are: FHD-286, which is a selective, allosteric and small-molecule, enzymatic inhibitor of BRG1 and BRM, that it is developing for the potential treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, which is a selective and intravenous, small molecule protein degrader of BRD9, a component of a form of the BAF complex that Co. is developing in clinical study in synovial sarcoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
30,672 |
30,672 |
41,672 |
352,969 |
Total Sell Value |
$297,131 |
$297,131 |
$369,265 |
$2,937,465 |
Total People Sold |
2 |
2 |
3 |
4 |
Total Sell Transactions |
3 |
3 |
4 |
5 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gottschalk Adrian |
Chief Executive Officer |
|
2021-08-20 |
4 |
OE |
$0.54 |
$12,420 |
D/D |
23,000 |
446,479 |
|
- |
|
Reine Allan |
Chief Financial Officer |
|
2021-08-09 |
4 |
OE |
$3.72 |
$100,038 |
D/D |
26,892 |
53,784 |
|
- |
|
Smith Ian F |
|
|
2021-04-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
72,072 |
|
- |
|
Afeyan Noubar |
10% Owner |
|
2020-10-27 |
4 |
B |
$16.00 |
$2,400,000 |
I/I |
150,000 |
1,851,801 |
1.5 |
- |
|
Afeyan Noubar |
10% Owner |
|
2020-10-27 |
4 |
A |
$0.00 |
$0 |
I/I |
12,524,120 |
1,801,801 |
|
- |
|
Gottschalk Adrian |
See Remarks |
|
2020-10-27 |
4 |
A |
$0.00 |
$0 |
I/I |
25,225 |
25,225 |
|
- |
|
Decicco Carl |
Chief Scientific Officer |
|
2020-10-27 |
4 |
B |
$16.00 |
$88,000 |
D/D |
5,500 |
258,397 |
2.74 |
- |
|
Platinum Falcon B 2018 Rsc Ltd |
Former 10% Owner |
|
2020-10-27 |
4 |
B |
$16.00 |
$2,400,000 |
D/D |
150,000 |
1,231,081 |
0.01 |
- |
|
Platinum Falcon B 2018 Rsc Ltd |
Former 10% Owner |
|
2020-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,081,081 |
1,081,081 |
|
- |
|
Bellon Steven F. |
See RemarksOfficer |
|
2020-10-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
128,378 |
|
- |
|
Gottschalk Adrian |
See RemarksOfficer |
|
2020-10-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
423,479 |
|
- |
|
Kadoch Cigall |
Director |
|
2020-10-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,957,712 |
|
- |
|
Decicco Carl |
Chief Scientific OfficerOffice |
|
2020-10-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
252,897 |
|
- |
|
Baselga Jose |
Director |
|
2020-10-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
94,594 |
|
- |
|
Reine Allan |
Chief Financial OfficerOfficer |
|
2020-10-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,892 |
|
- |
|
40 Records found
|
|
Page 2 of 2 |
|
|